Interactions of cantharidin-like inhibitors with human protein phosphatase-5 in a Mg2+ system: molecular dynamics and quantum calculations
Language English Country Germany Media electronic
Document type Journal Article
PubMed
30280322
DOI
10.1007/s00894-018-3837-y
PII: 10.1007/s00894-018-3837-y
Knihovny.cz E-resources
- Keywords
- AIM, Cantharidin-like inhibitors, Molecular dynamics, QM/MM, Serine/threonine phosphatase 5,
- MeSH
- Magnesium chemistry MeSH
- Enzyme Inhibitors pharmacology MeSH
- Nuclear Proteins antagonists & inhibitors chemistry MeSH
- Cantharidin analogs & derivatives chemistry pharmacology MeSH
- Catalytic Domain MeSH
- Cations, Divalent chemistry MeSH
- Humans MeSH
- Phosphoprotein Phosphatases antagonists & inhibitors chemistry MeSH
- Drug Design MeSH
- Molecular Dynamics Simulation * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Magnesium MeSH
- Enzyme Inhibitors MeSH
- Nuclear Proteins MeSH
- Cantharidin MeSH
- Cations, Divalent MeSH
- protein phosphatase 5 MeSH Browser
- Phosphoprotein Phosphatases MeSH
The serine/threonine protein phosphatase type 5 (PP5) is a promising target for designing new antitumor drugs. This enzyme is a member of the PPP phosphatases gene family, which catalyzes a dephosphorylation reaction: a regulatory process in the signal transduction pathway that controls various biological processes. The aim of this work is to study and compare the inhibition of PP5 by ten cantharidin-like inhibitors in order to bring about contributions relevant to the better comprehension of their inhibitory activity. In this theoretical investigation, we used molecular dynamics techniques to understand the role of key interactions that occur in the protein active site; QM calculations were employed to study the interaction mode of these inhibitors in the enzyme. In addition, atoms in molecules (AIM) calculations were carried out to characterize the chemical bonds among the atoms involved and investigate the orbital interactions with their respective energy values. The obtained results suggest that the Arg275, Asn303, His304, His352, Arg400, His427, Glu428, Val429, Tyr451, and Phe446 residues favorably contribute to the interactions between inhibitors and PP5. However, the Asp271 and Asp244 amino acid residues do not favor such interactions for some inhibitors. Through the QM calculations, we can suggest that the reactional energy of the coordination mechanism of these inhibitors in the PP5 active site is quite important and is responsible for the inhibitory activity. The AIM technique employed in this work was essential to get a better comprehension of the transition states acquired from the mechanism simulation. This work offers insights of how cantharidin-like inhibitors interact with human PP5, potentially allowing the design of more specific and even less cytotoxic drugs for cancer treatments. Graphical Abstract Interactions of cantharidin-like inhibitors with human protein phosphatase-5 in a Mg2+ system.
See more in PubMed
Nucleic Acids Res. 2000 Jan 1;28(1):235-42 PubMed
J Mol Model. 2015 Jan;21(1):14 PubMed
Comb Chem High Throughput Screen. 2016;19(4):334-44 PubMed
J Chem Inf Model. 2009 Jun;49(6):1428-36 PubMed
J Med Chem. 2009 Aug 13;52(15):4838-43 PubMed
Cancer Metastasis Rev. 2008 Jun;27(2):169-78 PubMed
J Biomed Sci. 2014 Sep 20;21:84 PubMed
Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9009-14 PubMed
J Biol Chem. 2004 Aug 6;279(32):33992-9 PubMed
Cell. 2013 Dec 5;155(6):1199-202 PubMed
Biochem Pharmacol. 2016 Jun 1;109:14-26 PubMed
Int J Mol Sci. 2013 Dec 16;14(12):24501-13 PubMed
Expert Opin Ther Pat. 2016;26(3):389-407 PubMed
Chemistry. 2013 Oct 11;19(42):14081-9 PubMed
J Mol Graph. 1996 Feb;14(1):33-8, 27-8 PubMed
Int J Biochem Cell Biol. 2008;40(11):2358-62 PubMed
Trends Endocrinol Metab. 2001 Jan-Feb;12(1):28-32 PubMed
Angew Chem Int Ed Engl. 2009;48(7):1198-229 PubMed
Curr Med Chem. 2016;23(10):1041-61 PubMed
J Biomol Struct Dyn. 2015 Sep;33(9):2048-58 PubMed
Sci Rep. 2015 Jul 20;5:12359 PubMed
Cell. 2009 Oct 30;139(3):468-84 PubMed
Methods Enzymol. 2016;577:119-58 PubMed